Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746268 | 0.93 | CNR1 (0.88) | CNR1CNR2 | |
| SCHEMBL6070879 | 0.91 | CNR1 (0.84) | CNR1CNR2 | |
| SCHEMBL27240738 | 0.91 | CNR1 (0.83) | CNR1CNR2 | |
| SCHEMBL27003765 | 0.91 | CNR1 (0.83) | CNR1CNR2 | |
| SCHEMBL4692867 | 0.90 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4789214 | 0.89 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL4788579 | 0.89 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6070554 | 0.89 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4696620 | 0.89 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL6070803 | 0.88 | CNR1 (0.79) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874779-A1 | ACYLAMINOBICYCLIC HETEROMATIC COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2008-01-09 | — | — | EP | claimed |
| US-20060241100-A1 | Acylaminobicyclic heteroaromatic compounds and uses thereof | PFIZER INC | 2006-10-26 | — | — | US | claimed |
| WO-2006111849-A1 | ACYLAMINOBICYCLIC HETEROMATIC COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-10-26 | — | — | WO | claimed |
| US-20060241100-A1 | Acylaminobicyclic heteroaromatic compounds and uses thereof | PFIZER INC | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241100-A1 | Acylaminobicyclic heteroaromatic compounds and uses thereof | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.